Applied Evidence

Migraine: Expanding our Tx arsenal

Author and Disclosure Information

 

References

In both studies, the risk of adverse drug events due to onabotulinumtoxinA was high and led to a significant rate of discontinuation.33,43 Despite this, onabotulinumtoxinA remains the only Food and Drug Administration (FDA)–approved treatment for chronic migraine, making it reasonable to consider for appropriate patients.

Acupuncture. A 2016 Cochrane review found benefit for patients using acupuncture compared with sham acupuncture.34 When acupuncture was compared with prophylactic agents such as beta-blockers, calcium-channel blockers, and anti-epileptics, however, there was no significant difference between the procedure and pharmacotherapy. Patients willing and able to try acupuncture might see a reduction in the overall number of headaches. Acupuncture has few adverse effects; however, long-term data are lacking.34

Exercise is not supported by robust data for its role as a prophylactic treatment. It is generally considered safe in most populations, however, and can be pursued with little out-of-pocket cost.35

Cognitive behavioral therapy (CBT). The AAN recommends CBT, relaxation therapy, and biofeedback therapy. Accessibility of these services remains limited for many patients, and cost can be prohibitive.16

Supplements used to help prevent migraine include the root of Petasites hybridus (butterbur), magnesium, vitamin B2 (riboflavin), Tanacetum parthenium (feverfew), and coenzyme Q10.16 Although the strength of evidence for these therapies is limited by small trials, their overall risk of adverse effects is low, and they might be easier for patients to obtain than acupuncture or CBT.

Continue to: Butterbur, in particular...

Pages

Recommended Reading

Active migraine in women linked to lower risk of developing T2DM
Journal of Clinical Outcomes Management
Can higher MAP post cardiac arrest improve neurologic outcomes?
Journal of Clinical Outcomes Management
Can lifestyle modifications delay or prevent Alzheimer’s disease?
Journal of Clinical Outcomes Management
Cerebral small vessel disease progression linked to MCI in hypertensive patients
Journal of Clinical Outcomes Management
Researchers exploring ways to mitigate aging’s impact on diabetes
Journal of Clinical Outcomes Management
Autologous Hematopoietic Stem Cells May Treat Aggressive MS Effectively
Journal of Clinical Outcomes Management
Population-level rate of SUDEP may have decreased
Journal of Clinical Outcomes Management
DMTs, stem cell transplants both reduce disease progression in MS
Journal of Clinical Outcomes Management
Obesity paradox applies to post-stroke mortality
Journal of Clinical Outcomes Management
How seizure prediction may benefit patients with epilepsy
Journal of Clinical Outcomes Management